Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bleomycin
Drug ID BADD_D00280
Description A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Indications and Usage For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
Marketing Status Prescription; Discontinued
ATC Code L01DC01
DrugBank ID DB00290
KEGG ID D07535
MeSH ID D001761
PubChem ID 5460769
TTD Drug ID D06UVD
NDC Product Code 61703-323; 0143-9240; 0703-3155; 16714-908; 0409-0332; 61703-332; 16714-886; 0143-9241; 70121-1567; 0703-3154; 0409-0323; 69097-364
Synonyms Bleomycin | Bleomycins | BLEO-cell | BLEO cell | BLEOcell | Bleolem | Bléomycine Bellon | Bellon, Bléomycine | Bleomycin A2 | Bleomycin A(2) | Bleomycin B2 | Bleomycin B(2) | Bleomycin Sulfate | Sulfate, Bleomycin | Bleomycinum Mack | Mack, Bleomycinum | Blenoxane | Blanoxan | Bleomicina
Chemical Information
Molecular Formula C55H84N17O21S3+
CAS Registry Number 11056-06-7
SMILES CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O) OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6 =NC(=CS6)C(=O)NCCC[S+](C)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tenderness08.01.08.005--Not Available
Thrombocytopenia01.08.01.0020.002398%Not Available
Thrombotic microangiopathy24.01.01.013; 20.01.07.004; 01.01.02.006--Not Available
Tumour pain16.32.03.003--
Ulcer08.03.06.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Wheezing22.03.01.009--
Acute generalised exanthematous pustulosis23.03.10.002; 12.03.01.0050.000533%Not Available
Pneumomediastinum22.09.03.0040.000533%Not Available
Deep vein thrombosis24.01.02.0030.000139%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Bone marrow toxicity12.03.01.006; 01.03.03.0040.000533%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Metaplasia08.03.04.004--Not Available
Haemorrhage24.07.01.002--Not Available
Pleuropericarditis22.05.01.002; 02.06.02.003--Not Available
Skin toxicity23.03.03.032; 12.03.01.020--Not Available
Fraction of inspired oxygen25.13.01.002--Not Available
Induration08.01.03.020--Not Available
Cranial nerve disorder17.04.01.0010.000533%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.001737%Not Available
Renal impairment20.01.03.0100.001332%Not Available
Cystitis noninfective20.03.02.001--
Bone marrow failure01.03.03.0050.000625%
Dysmorphism15.11.06.001; 03.11.06.0010.000208%Not Available
Acute interstitial pneumonitis22.01.02.016--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages